11/5/2026

speaker
Kevin Trask
Chief Financial Officer

Good afternoon and welcome to Syntax Technologies' third quarter 2026 earnings conference call. All participants are in listen-only mode. As a reminder, today's call is being recorded. I would now like to turn the call over to Syntax Technologies' chief legal officer, Kevin Ontiveros.

speaker
Kevin Ontiveros
Chief Legal Officer

Thank you, operator, and good afternoon, everyone. Earlier today, Syntex Technologies released its financial results for the quarter-ended September 30, 2026, and filed its quarterly report on Form 10-Q with the Securities and Exchange Commission. These materials, together with a replay of this call, will be available through the investor relations section of the Syntex Technologies website. Before we begin, I want to remind listeners that statements on today's call, other than historical facts, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These include statements about customer orders, production and shipment schedules, future revenue and guidance, gross margins, medical device commercialization, surgeon and distributor adoption, Research and Development, Intellectual Property, Strategic Relationships, Potential Financing and Warrant Exercises, Liquidity and Business Outlook. They reflect current expectations, involve risks and uncertainties, and actual results may differ materially. Please review the risk factors and other disclosures in our latest Forms 10-K and 10-Q and subsequent SEC filings. Syntex undertakes no duty to update these statements except as required by law. Unless otherwise noted, financial measures discussed today are presented on a US GAAP basis. Joining me are Eric Olson, our Chairman and Chief Executive Officer, and Kevin Trask, our Chief Financial Officer. Eric will provide the business and strategic update. Kevin will review financial results and liquidity, and Eric will close with our near-term priorities. At this time, I would like to turn the call over to Eric Olson. Eric?

speaker
Eric Olson
Chairman and Chief Executive Officer

Thank you, Kevin, and thank you to everyone for joining today's call. Our third quarter performance marks an important step in Syntex's transition into a commercially driven advanced biomaterials company. For many years, the strength of Syntex has been its silicon nitride technology, manufacturing expertise, and research and development capabilities. Today, we can announce that we have translated these strengths into sustainable commercial revenue and gross profits. I would like to highlight several third quarter takeaways. First, Syntex has manufactured and delivered more silicon nitride parts than in any other quarter in the company's history. Third quarter revenue grew 953% reaching approximately 2.2 million compared with 208,000 a year earlier. This represents a meaningful step up in demonstrating commercial scale driven primarily by our industrial and aerospace ceramics manufacturing operations. Second, gross profits reached approximately 1.4 million while our net loss narrowed by 55% year over year. Third, achieving the Q3 revenue milestone allowed us to execute a warrant call which resulted in gross capital proceeds of approximately $2 million, as well as the expiration of unexercised warrants that would have covered the issuance of an additional 941,000 shares, reducing the dilution to existing shareholders. We anticipate the revenue from the industrial sales vertical will support us as we continue our transition to addressing unmet needs in medical devices and medical textiles while also working to bring our cost structure more in line with our revenue. The update we will discuss today reinforces both our short and long-term business strategies focused on, first, industrial and aerospace revenue growth, second, commercialization of our FDA-cleared Sanaptic Silicon Nitride System for foot and ankle procedures. Third, moving our silicon nitride peak, 3D printed orthopedic implants closer to commercialization. And fourth, the licensing of silicon nitride treated medical textiles for wound closure and wound care applications. These strategies are possible thanks to our one-of-a-kind vertically integrated manufacturing facility, the only facility registered with the FDA to manufacture medical grade silicon nitride biomaterials. This manufacturing capability combined with our recent patents for integrating silicon nitride into composites and textiles has allowed our platform to begin moving forward beyond traditional orthopedic devices and into other exciting biotech applications. As the only global manufacturer of medical grade silicon nitride, we believe our priorities reflect a business that is not just about a single quarter's growth. It is about our ability to leverage a biomaterial platform to convert customer demand into delivered products and overall revenue growth. With that context in mind, I'd like to begin discussing our revenue growth in Q3 and what that means for the future of our silicon nitride business. Industrial manufacturing remained the primary contributor to third quarter revenue. Our experience in material formulation, precision manufacturing, and repeatable processing gives us an opportunity to deepen relationships with established industrial customers who need reliable components that perform in demanding environments. Purchase orders received this year from Fortune 500 aerospace companies informed the guidance We offered in our second quarter earnings call where we indicated an expected revenue range of $900,000 to $1.1 million for the third quarter. Our ability to double the high end of these expectations is not only a testament of customer satisfaction, it is also a reflection of improvements in our manufacturing and operational efficiencies. Importantly, this execution demonstrated our capacity to manufacture at scale, which will become even more critical when applied to our medical device manufacturing throughput. As we discussed in our previous calls, receipt of these purchase orders represented the beginning of the work, not the completion of it. We indicated then that the important milestones included repeatable production, manufacturing yield, on time delivery and recognized revenue. We are pleased to report that we have demonstrated objective success in achieving these milestones and on an accelerated basis. Our ambition is to turn the success into a durable commercial foundation, that is increasing capacity, obtaining repeat orders and generating revenue that can support further development of our proprietary biomaterial platform. We are also expanding our dialogue with prospective manufacturing partners where our ceramic expertise can help solve specific technical challenges. The revenue from industrial sales provides an important source of growth and operational leverage as we expand our medical device and biomaterial platforms. To provide some quick background for listeners new to the Syntex story, The unique molecular properties of silicon nitride make it the ideal biomaterial for medical devices. Silicon nitride has several material characteristics that we believe make it attractive for medical device applications. These properties include being naturally antipathogenic and antimicrobial, which may decrease the likelihood of revision surgery during or due to infection. and osteoconduction, or the ability to stimulate bone growth, which could accelerate natural healing and help to prevent implant failures in the future. Implant-associated infections cost the US healthcare system approximately $3 to $5 billion every year. Once bacteria adhere to implants made of other materials, such as metal or plastic, the bacteria becomes more resistant to antibiotics. Siliconitride, on the other hand, has been shown to not only inhibit the bacterial attachment in the first place, but to actually kill the bacteria as well. Published studies regarding Siliconitride have shown that these features may help to accelerate patient healing while also being less likely to cause allergic reactions and also provide more clear radiographic visibility than any other material, allowing for precise placement of implants in critical anatomic locations. Our lead proprietary siliconitride product in this vertical remains the FDA 510 cleared synaptic foot and ankle wedge system. This implant system entered clinical use in the United States earlier this year and we have begun the process of building a commercial channel around it. As you may recall, the synaptic system consists of siliconitride wedges which are being used in reconstructive procedures including those to correct mid and high foot pathologies and potentially for sports medicine applications as well. Following the completion of our limited use release that we have discussed in our previous call, full commercialization has now begun with distributors targeting the lead foot and ankle surgeons in the United States while we also explore other strategic opportunities with partners that have existing relationships with facilities and Foot and Ankle Surgeons. Commercial success of the system will be measured through surgeon adoption, product availability, repeat procedures or stickiness and meaningful revenue. We are also evaluating capital efficient routes to market and we intend to build effective distribution and clinical support models while maintaining manufacturing and quality discipline. Beyond monolithic silicon nitride implants, our technology initiatives are intended to extend silicon nitride into new material formats and applications, including polymer composites and 3D manufacturing. We are pursuing commercialization strategies for patient-specific and custom implants, and we are entering into collaboration with partners who have the design, regulatory, and distribution capabilities needed to bring advanced products to market. We also continue to assess applications involving medical textiles, wound care, wound management, and other potential antipathogenic applications. 3D printing of orthopedic implants allow us to distribute a vast array of AI-assisted custom and patient-specific implants with complex geometries and patient-specific designs that may be difficult to achieve using traditional manufacturing methods. We believe these capabilities create new opportunities for our silicon nitride PEAK biocomposite platform. Last year, we announced the manufacturing agreement with Evonik, a leading global manufacturer of PEAK and PEAK-based filaments for 3D printing applications. Operating under our patent and using silicon nitride material provided by Syntex, Evonik produces a commercial-scale composite filament of PEAK and silicon nitride for these 3D printed devices. Our patented silicon nitrate peak biocomposite, which will be marketed as part of our quote synergy biocomposite platform, combines the characteristics of these two materials and may offer advantages for certain orthopedic applications. We anticipate that 3D printing using the filament provided by Evonik may result in greater manufacturing yields, lower cost of goods, and less waste material than other manufacturing processes. Already, Syntex manufacturing and innovation teams have created a new 3D printing manufacturing facility and have also begun developing the custom workflows for these 3D printed implant applications. Syntex is also currently conducting large animal in vivo studies to evaluate the effectiveness of medical textiles treated with silicon nitride and to advance preclinical work evaluating the antimicrobial and anti-adhesion scar reduction properties of silicon nitride treated sutures and wound dressings for various wound healing and wound management applications. We anticipate that these studies will be completed in the next calendar quarter. These large animal studies are intended to help generate data regarding the healing performance of these materials in relevant wound environments and to inform future development and potential commercial partnering activities. We believe this represents a promising opportunity to extend our siliconitride technology platform beyond traditional orthopedic implants. Ongoing testing and applicable regulatory clearances or approvals will be required before the commercialization or licensing of any resulting medical devices. The long-term vision is to create a licensing platform that would allow partners to integrate patented siliconitride technologies into their own medical textiles. We expect the outcome of these studies to inform the commercial strategy for these particular wound care and wound management applications and look forward to providing updates on the study's progress. To conclude, the milestones we have discussed today reflect a record quarter of meaningful execution across all of our core strategic priorities. While each of these initiatives are important on their own, together they demonstrate the progress we are making towards commercialization, and the long-term strategy we have previously outlined. With that, I will turn the call over to our Chief Financial Officer, Kevin Trask, for more details on the quarter's financial results.

Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-

Use this data in your own app

Pull this call's transcript, audio and slides with the Earnings call transcripts API.

See pricing

9,000+ companies · REST API